A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients With Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients with Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927.

Inclusion Criteria:

• The participant is deemed healthy by the principal investigator, as determined by prestudy medical evaluation
• The participant voluntarily agrees to participate in this study and signs an institutional review board approved informed consent

Exclusion Criteria:

• The participant has any concurrent disease or condition that, in the opinion of the principal investigator, would make the participant unsuitable for participation in the clinical study